Novel phenylamino pyrimidine derivatives as potent and selective inhibitors of ABL1 tyrosine kinase for targeted anticancer therapy
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.109709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Dilpreet Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Sciences, Chitkara University, Institute of Engineering & Technology, Chitkara University, Punjab, India; Chemical Research and…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-abl, Pyrimidines, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
Phenyl amino pyrimidine (PAP) derivatives represent a promising scaffold in anticancer drug discovery due to their potential to selectively inhibit tyrosine kinase (TK) enzymes implicated in tumor progression. In the present study, we designed a focused ligand library using bioisosteric substitutions in the imatinib structure to improve its target affinity and pharmacokinetic properties. Molecular docking confirmed the high-affinity of the designed compounds against the human proto-oncogene tyrosine-protein kinase ABL1 (PDB ID: 2hyy), and eight potential leads were synthesized based upon their key interactions within the target's ATP-binding pocket. The synthetic routes for these molecules followed a robust multi-step protocol, yielding pure compounds characterized comprehensively by NMR, HRMS, and chromatographic analyses, confirming structural integrity and purity. Cellular cytotoxicity assays demonstrated potent antiproliferative effects of these derivatives against DLD-1, HCT-116, and HT-29 colorectal cancer cell lines, exhibiting superior efficacy and selectivity (SI) compared to the benchmark drug imatinib mesylate (IC50 = 18.3 μM; SI = 1.36). Based on docking score and experimental outcome in cell viability assays, two lead compounds DS37 (IC50 = 3.11 μM; SI > 16) and DS42 (IC50 = 11.9 μM; SI > 16.8) were selected for further validation through 100 ns molecular dynamics simulations for their mechanistic establishment with ABL1. These studies confirmed their stable binding modes and dynamic conformational compatibility with the TK active site.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Sciences, Chitkara University, Institute of Engineering & Technology, Chitkara University, Punjab, India; Chemical Research and Development Division, Synthimed Labs Pvt. Ltd, Mohali-160055, India.
- Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland; Doctoral School of Exact and Natural Sciences, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland. Electronic addre…
- Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.
- School of Sciences, RIMT University, Punjab, India.
- Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India. Electronic address: somduttmujwar@gmail.com.
Zitieren
APA
Singh, D., Wanke, K., Kciuk, M., Marciniak, B., Kontek, R., Sharma, S. C., & Mujwar, S. (2026). Novel phenylamino pyrimidine derivatives as potent and selective inhibitors of ABL1 tyrosine kinase for targeted anticancer therapy. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109709
Vancouver
Singh D, Wanke K, Kciuk M, Marciniak B, Kontek R, Sharma SC, et al. Novel phenylamino pyrimidine derivatives as potent and selective inhibitors of ABL1 tyrosine kinase for targeted anticancer therapy. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109709
BibTeX
@article{Singh2026,
author = {Singh, Dilpreet and Wanke, Katarzyna and Kciuk, Mateusz and Marciniak, Beata and Kontek, Renata and Sharma, Sumesh Chandra and Mujwar, Somdutt},
title = {Novel phenylamino pyrimidine derivatives as potent and selective inhibitors of ABL1 tyrosine kinase for targeted anticancer therapy},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.109709}
}
EUVIMED